Malara, Angela Eliana (2010) Effects of three different anti-ErbB2 antibodies on prostate tumors. [Tesi di dottorato] (Unpublished)

[img]
Preview
PDF
Malara_Angela_Eliana_23.pdf

Download (691kB) | Preview
[error in script] [error in script]
Item Type: Tesi di dottorato
Resource language: English
Title: Effects of three different anti-ErbB2 antibodies on prostate tumors
Creators:
CreatorsEmail
Malara, Angela Elianaeliana.malara@unina.it
Date: 29 November 2010
Number of Pages: 30
Institution: Università degli Studi di Napoli Federico II
Department: Biologia strutturale e funzionale
Scuola di dottorato: Scienze biologiche
Dottorato: Biochimica e biologia cellulare e molecolare
Ciclo di dottorato: 23
Coordinatore del Corso di dottorato:
nomeemail
Arcari, Paoloarcari@unina.it
Tutor:
nomeemail
De Lorenzo, Claudiacladelo@unina.it
Date: 29 November 2010
Number of Pages: 30
Keywords: ErbB2-Prostate cancer
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/10 - Biochimica
Date Deposited: 09 Dec 2010 16:49
Last Modified: 17 Jun 2014 06:02
URI: http://www.fedoa.unina.it/id/eprint/8140

Collection description

Prostate cancer is the most commonly diagnosed malignancy in men in developed countries. ErbB2 contributes to prostate cancer progression by activating the androgen receptor in a steroid poor environment, thus promoting androgen-independent cell growth and survival. The consequent development of hormone refractory tumors is a major obstacle in prostate cancer therapy. The inhibition of ErbB2 signal transduction pathways by the use of human antibodies has been considered as a valuable alternative strategy for cancer therapy. Herein we report a comparative analysis of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (Trastuzumab), 2C4 (Pertuzumab), and Erb-hcAb, a novel fully human compact antibody produced in our laboratory. We demonstrate that the in vitro and in vivo growth of both androgen- dependent and –independent prostate cancer cells is efficiently inhibited by Erb-hcAb, which shows antitumor effects on some cell lines more potent than those observed for either Herceptin or 2C4

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item